Tempest Therapeutics Acquires CAR-T Assets, Burns Cash Amid Leadership Shift
Event summary
- Tempest Therapeutics (TPST) acquired a portfolio of dual-targeting CAR-T assets from Factor Bioscience in an all-stock transaction.
- Matt Angel, Ph.D., has been appointed CEO & President of Tempest Therapeutics.
- Interim data from the REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma (rrMM) showed a 100% complete response rate among six evaluable patients.
- Tempest ended 2025 with $7.7 million in cash, a significant decrease from $30.3 million in 2024, funded by ~$8.5 million in registered direct offerings.
- Tempest received clearance to proceed with a pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China.
The big picture
Tempest's acquisition of Factor Bioscience's CAR-T assets represents a bet on next-generation therapies in a crowded and competitive oncology market. The company's rapid cash depletion, however, raises concerns about its long-term financial stability and reliance on dilutive financing. The appointment of a new CEO signals a potential shift in strategy, but execution risks remain significant given the company's current financial position.
What we're watching
- Clinical Efficacy
- The sustainability of the 100% complete response rate observed in the REDEEM-1 trial will be critical to TPST-2003’s commercial viability, and the upcoming Phase 2b trial will be a key inflection point.
- Capital Needs
- Given the substantial cash burn and reliance on equity offerings, Tempest’s ability to secure additional funding will dictate its operational runway and pipeline advancement.
- Integration Risk
- The integration of the acquired CAR-T assets and the leadership transition under Matt Angel could impact the company’s strategic direction and execution capabilities.
Related topics